These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 31655197

  • 1. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
    Cheng N, Liu Y, Zhao G, Xu Y, Zhang T, Chen Y, Yan G, Hu Y, Yao S, Wang Z, Wang C, Chen Z, Hu Z, Liu D, Chen T.
    Int J Radiat Oncol Biol Phys; 2020 Feb 01; 106(2):340-348. PubMed ID: 31655197
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
    Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z.
    Int J Radiat Oncol Biol Phys; 2018 Mar 01; 100(3):730-737. PubMed ID: 29248169
    [Abstract] [Full Text] [Related]

  • 3. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
    Ren XJ, Wang L, Han C, Liu LL.
    Zhonghua Zhong Liu Za Zhi; 2019 Feb 23; 41(2):135-139. PubMed ID: 30862144
    [Abstract] [Full Text] [Related]

  • 4. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
    Wang L, Liu L, Cao Y, Chen X, Liu S, Li X, Han J, Wang Q, Han C.
    BMC Cancer; 2024 Jun 04; 24(1):679. PubMed ID: 38831450
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
    Gao LR, Wang X, Han W, Deng W, Li C, Wang X, Zhao Y, Ni W, Chang X, Zhou Z, Deng L, Wang W, Liu W, Liang J, Zhang T, Bi N, Wang J, Zhai Y, Feng Q, Lv J, Li L, Xiao Z.
    BMC Cancer; 2020 Sep 22; 20(1):901. PubMed ID: 32962674
    [Abstract] [Full Text] [Related]

  • 11. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC, Herndon JE, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M.
    J Clin Oncol; 1998 Nov 22; 16(11):3528-36. PubMed ID: 9817271
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I Study.
    Sakanaka K, Ishida Y, Fujii K, Ishihara Y, Nakamura M, Hiraoka M, Mizowaki T.
    Clin Oncol (R Coll Radiol); 2021 Mar 22; 33(3):191-201. PubMed ID: 32768158
    [Abstract] [Full Text] [Related]

  • 14. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
    Lin Q, Liu YE, Ren XC, Wang N, Chen XJ, Wang DY, Zong J, Peng Y, Guo ZJ, Hu J.
    Radiat Oncol; 2013 Aug 17; 8(1):201. PubMed ID: 23957889
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N, Park SD, Lynch T, Wright C, Ancukiewicz M, Wain J, Donahue D, Mathisen D.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):111-22. PubMed ID: 15337546
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.